HT
LGND icon

Headlands Technologies’s Ligand Pharmaceuticals LGND Stock Holding History

Headlands Technologies’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-828
Closed -$88.7K – 1358
2024
Q4 		$88.7K Buy
828
+18
+2% +$2.04K 0.01% 690
2024
Q3 		$81.1K Buy
810
+52
+7% +$5.24K 0.01% 715
2024
Q2 		$63.9K Buy
758
+135
+22% +$10.7K 0.01% 731
2024
Q1 		$45.5K Sell
623
-341
-35% -$25.1K 0.01% 744
2023
Q4 		$68.8K Sell
964
-409
-30% -$24.1K 0.02% 466
2023
Q3 		$82.3K Sell
1,373
-240
-15% -$15.8K 0.04% 347
2023
Q2 		$116K Buy
+1,613
New +$121K 0.04% 365

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Headlands Technologies's LGND Position: Q1 2025 in Review

Headlands Technologies sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 828 shares — an estimated $88.7K sold.

Headlands Technologies first reported a position in LGND in Q2 2023 and held it in 7 quarters. The position peaked at $116K in Q2 2023. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • Headlands Technologies reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Headlands Technologies sold 828 Ligand Pharmaceuticals shares in Q1 2025, an estimated $88.7K.
  • Headlands Technologies first reported a position in Ligand Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Headlands Technologies's Ligand Pharmaceuticals position peaked at $116K in Q2 2023.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Headlands Technologies's 13F filing for Q1 2025, filed 9 May 2025.